Ischaemic preconditioning and myocardial adaptation to serial intracoronary balloon inflation: cut from the same cloth?

M E Faircloth, S R Redwood, M S Marber

Elective percutaneous coronary intervention fulfils many of the criteria needed of a clinical model of ischaemic preconditioning. But is this really a reflection of the laboratory phenomenon of ischaemic preconditioning?

The term “ischaemic preconditioning” was first coined in 1986 by Murry and colleagues, to describe a cardioprotective phenomenon that follows brief periods of myocardial ischaemia and that manifests during subsequent prolonged ischaemia. In this original description the magnitude of protection was substantial, reducing the volume of myocardial infarct by 75–80%. Over the next few years the potency and reproducibility of this phenomenon was confirmed in numerous studies conducted on perfused isolated, and in situ, animal hearts. These animal studies were designed to test whether preconditioning was initiated or prevented by various pharmacological interventions before myocardial ischaemia of sufficient duration to cause infarction. Studies with such a design could obviously not be replicated in patients. The lack of definitive studies in patients fostered uncertainty as to whether ischaemic preconditioning could be “bottled” to benefit patients. What was urgently needed was a robust model of ischaemic preconditioning in patients where myocardial ischaemia could be controlled and measured. Such a model could then be used to determine if the mechanisms underlying “true” preconditioning against infarction in animals could be reciprocated in patients and therefore have the potential to be translated into new treatment.

Is myocardial adaptation to serial balloon occlusion during PCI a model of ischaemic preconditioning?

Elective percutaneous coronary intervention fulfils many of the criteria needed of a clinical model of ischaemic preconditioning. The timing of myocardial ischaemia can be controlled during repeated intracoronary balloon occlusions. The severity of the consequent myocardial ischaemia can be measured by the amplitude of ST segment elevation on the surface and intracoronary ECG, segmental contractile dysfunction, frequency of ventricular dysrhythmia, and/or patients’ anginal discomfort.

Many studies have used balloon occlusion during PCI to demonstrate that at similar durations of occlusion there is an attenuation of these manifestations of myocardial ischaemia on successive, compared to first, occlusion. The question is whether this really is a reflection of the laboratory phenomenon of ischaemic preconditioning.

There are four principle determinants of the severity of myocardial ischaemia. The first two—duration of ischaemia and volume of myocardium perfused beyond the target lesion—can be controlled or do not vary appreciably between successive balloon inflations, and therefore cannot explain adaptation under these circumstances. The third factor is the amount of collateral myocardial blood flow during coronary occlusion. Previous studies have attempted to control for this by including only those patients without angiographically visible collaterals and others, and we have also excluded this contribution by measuring distal intracoronary balloon occlusion pressure. The remaining factor is the endogenous resistance of the myocardium to ischaemia. The only phenomenon, other than hypothermia and/or cardioplegia, that can reproduce increase endogenous myocardial resistance is ischaemic preconditioning. Thus, many investigators believe that the clinical phenomenon of myocardial adaptation to serial balloon occlusion is synonymous with the laboratory phenomenon of ischaemic preconditioning against infarction. However, if this is the case it should also share the pharmacological signature of preconditioning. The receptor and channel dependence of ischaemic preconditioning in animals has been investigated intensively and involves the opening of an ATP dependent potassium channel (KATP), in either the sarcolemma or mitochondrion, that can be blocked by glibenclamide and opened by nicorandil and pinacidil.

“Observe due measure, for right timing is in all things the most important factor”—Hesiod (−800 BC)

In this issue, Lindhardt and colleagues have tested the KATP dependence of myocardial adaptation to repeated left anterior descending coronary artery occlusions during elective PCI carried out in the presence of pinacidil, glibenclamide, or placebo. The readouts of myocardial ischaemia were ST segment shift on the
surface ECG, angina severity score, and left ventricular (LV) dysfunction, measured by radionuclide ejection fraction. Patients with collaterals visible on their prior diagnostic coronary angiogram were excluded. Surprisingly there was no significant difference between and within the groups with regard to the amplitude of ST segment shift, decrement in LV function, or anginal severity on first versus subsequent balloon occlusions. The authors conclude, with qualifications, that the study does “not support the notion that the human myocardium has an intrinsic protective mechanism” and therefore does not exhibit ischemic preconditioning.

It is clear the Lindhardt study is carefully performed but yet the findings are, on the surface, counterintuitive and therefore particularly notable and worthy of analysis. Does the study really mean intracoronary balloon occlusion can no longer be used as a surrogate of preconditioning? This seems unlikely since a number of other studies have demonstrated myocardial adaptation to serial balloon occlusion in a manner akin to ischemic preconditioning. Furthermore closer examination of the findings suggests that the threshold duration of ischemia below which occlusion adaptation in patients lies between 60–180 seconds. This is the duration of ischemia needed to initiate myocardial protection whereas one of 180 seconds did. Thus it seems the balloon inflation time of 60 seconds did not initiate adaptation or, that if it is, there is a gradated response that is precipitated or, that if it is, there is a gradated response that is

In the study by Lindhart and colleagues it is the duration of balloon occlusion was 90 seconds and the mean age of the patients in the groups expected to exhibit adaptation was 60 years. Thus it is likely that the duration of balloon occlusion was too brief to trigger adaptation. In contrast to the author’s interpretation one could argue that the study by Lindhart reinforces the temporal similarities between adaptation to serial balloon occlusion in patients and ischemic preconditioning in animals, while it is the finding of adaptation after only 90 seconds of balloon occlusion by the other investigators that is counterintuitive!

HOW RELEVANT ARE $K_{ATP}$ CHANNELS TO PROTECTION OF THE HUMAN HEART?

Another surprising finding in the study by Lindhart and colleagues is that pinacidil did not lessen the severity of myocardial ischemia during first balloon inflation compared to placebo. As mentioned previously, $K_{ATP}$ Channels play a definite role in ischemic preconditioning. However, consensus is lacking over the exact relation of these channels to the multiple, parallel, and variably redundant pathways that lead to protection. While two or more stimuli may initiate preconditioning when acting in concert, neither stimulus may be sufficient in isolation. This, together with other observations, suggests that preconditioning may be an “all or nothing” phenomenon. However, on balance, it is likely that instead there is a steep stimulus response curve, which masquerades as a binary response. This behaviour does impact on the findings of Lindhart and colleagues. For example, the observed tendency for ST segment elevation to be less on second inflation within placebo and pinacidil groups is more likely to relate to the presence of adaptation in a small subset of patients rather than a partial stimulus response in the whole patient group. Such interpretation of the negative findings becomes even more tenuous when examining responses to pinacidil and placebo across patient groups. This is especially so when there are few indications, such as reductions in systemic blood pressure and increases in heart rate, that the pinacidil concentrations achieved were sufficient to open myocardial $K_{ATP}$ channels.

As is probably apparent in the reading of this editorial, the clinical relevance of the laboratory phenomenon of ischemic preconditioning is as yet unclear, at least to us! This situation is little changed by the article of Lindhart and colleagues. However the authors are to be congratulated on completing a carefully designed and blinded clinical study based on laboratory findings in ischemic preconditioning and for not letting their negative findings bias their desire for publication. Without such attempts, discussion of the relation between the laboratory phenomenon of ischemic preconditioning and the clinical benefits of pre-infarction angina, insulin and glucose in acute myocardial infarction, and nicorandil in the IONA (impact of nicorandil in angina) study will be forever fated to hand waving.

Authors’ affiliations
M E Faircloth, S R Redwood, M S Marber, Department of Cardiology, Division of Cardiovascular Research, GKT School of Medicine, KCL, The Rayne Institute, St Thomas’ Hospital, London, UK.

REFERENCES

3. Reimer K, Jennings R. The “wavefront phenomenon” of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979;40:633–44.
Coronary thrombus in unstable angina: a moving target

A 55 year old male patient without previous cardiac history underwent coronary angiography because of angina pectoris (Canadian Cardiovascular Society class 3) and a positive exercise test. The right coronary artery and left anterior descending artery showed only mild irregularities, but the mid right circumflex (RCX) artery showed a luminal filling defect suggestive of thrombus just proximal to a severe stenosis (panel A). Left ventricular function was normal. The procedure was ended and it was decided to perform percutaneous coronary intervention of the RCX after 24 hours of pretreatment with a glycoprotein IIb/IIIa inhibitor. However, only minutes after completion of the procedure the patient complained of severe chest pain. Repeat angiography showed an occluded RCX (panel B). It was noted that a side-branch to the left atrium was now visible whereas it was not on the previous film, suggesting embolisation of a previously occluding thrombus. Immediate angioplasty of the RCX was performed, resulting in distal embolisation and no reflow (panel C), without any improvement after intracoronary papaverine. Subsequently, a thrombectomy device (Rescue catheter, Boston Scientific) was used in an attempt to remove thrombotic material and improve coronary flow. A red, organised thrombus (6 x 2 mm) was removed (lower panel). The final result of the procedure showed TIMI 3 flow and grade 3 myocardial blush (panel D). Maximum creatine kinase-MB was 29 mg/l, and left ventricular ejection fraction was 68% after two months.

This case illustrates one of the less frequent mechanisms of acute myocardial infarction—namely, embolisation of a coronary thrombus. Thrombus formation may have occurred due to turbulent flow just proximal to a severe stenosis.

JH E Dambrink, D M Nicastia
jhe.dambrink@diagram-zwolle.nl
Ischaemic preconditioning and myocardial adaptation to serial intracoronary balloon inflation: cut from the same cloth?
M E Faircloth, S R Redwood and M S Marber

Heart 2004 90: 358-360
doi: 10.1136/hrt.2003.025791

Updated information and services can be found at:
http://heart.bmj.com/content/90/4/358

These include:

References
This article cites 20 articles, 10 of which you can access for free at:
http://heart.bmj.com/content/90/4/358#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Interventional cardiology (2933)
Percutaneous intervention (964)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/